By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NexBio, Inc. 

10665 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-452-2631 Fax:


Start Up

Company News
NexBio, Inc. Anti-Flu Drug Reduces Virus in Trial to Seek New Therapy 9/20/2011 7:47:13 AM
NexBio, Inc.’s DAS181 (Fludase(R)) Improves Symptoms in Four Severely Immunocompromised Patients With Life-Threatening Parainfluenza Pneumonitis 8/31/2011 6:16:46 AM
NexBio, Inc. Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 8/15/2011 10:46:07 AM
Feds Raid San Diego Vaccine Developer NexBio, Inc. 8/5/2011 8:01:46 AM
NexBio, Inc.’s DAS181 (Fludase(R)*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 2/17/2011 8:30:48 AM
NexBio, Inc. Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase) 11/11/2010 11:51:55 AM
NexBio, Inc. and Weill Cornell Medical College Publish Preclinical Study Showing DAS181 (Fludase(R)*) Anti-Influenza Drug Inhibits Parainfluenza Virus 6/18/2010 9:45:02 AM
NexBio, Inc.: Clinical Trial of DAS181 (Fludase(R)*) in Asthmatics Initiated at the National Institutes of Health (NIH) 5/3/2010 11:05:54 AM
NexBio, Inc. Publishes Preclinical Study Showing DAS181 (Fludase(R)*) Anti-Influenza Therapy Protects Against Secondary Bacterial Pneumonia 3/29/2010 8:47:23 AM
NexBio, Inc. Granted United States Patent Covering DAS181 (Fludase(R) *) and its Use for Prevention and Treatment of Influenza and Parainfluenza 2/9/2010 7:31:40 AM